SPAS(SH:603168)2024-07-09 08:28Financial Performance Expectations - The company expects a net profit attributable to shareholders of the parent company for the first half of 2024 to be between -19.8 million and -29.5 million yuan, excluding non-recurring gains and losses [3][8][7]. - In the same period last year, the net profit attributable to shareholders was 73.35 million yuan, with a net profit of 60.12 million yuan after excluding non-recurring gains and losses [10]. Reasons for Expected Loss - The primary reasons for the expected loss include a decrease in revenue from eye drops and cephalosporins compared to the same period last year, and an increase in R&D expenses due to accelerated project progress [11]. Earnings Forecast and Risks - The earnings forecast data is preliminary and has not been audited by a registered accountant, with no significant uncertainties affecting the accuracy of the forecast [12][9]. - The company emphasizes the importance of investors being aware of investment risks as the final financial data will be disclosed in the official 2024 semi-annual report [13].